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Effect of a phosphodiesterase-5A 
(PDE5A) gene polymorphism on 
response to sildenafil therapy in 
canine pulmonary hypertension
Yu Ueda, Lynelle R. Johnson, Eric S. ontiveros, Lance C. Visser, Catherine T. Gunther-Harrington & 
Joshua A. Stern
Pulmonary hypertension (PH) is a common clinical condition associated with morbidity and 
mortality in both humans and dogs. Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor causing 
accumulation of cGMP, is frequently used for treatment of PH. The authors previously reported a 
PDE5A:E90K polymorphism in dogs that results in lower basal cyclic guanosine monophosphate 
(cGMP) concentrations than in wild-type dogs, which could contribute to variability in the efficacy of 
sildenafil. In this study, response to sildenafil therapy was evaluated in dogs with PH by comparing 
echocardiographic parameters, quality-of-life (QOL) score, and plasma cGMP concentrations before 
and after sildenafil therapy. Overall, tricuspid regurgitation estimated systolic pressure gradient (PG) 
and QOL score were significantly improved after sildenafil therapy, and the plasma cGMP concentration 
was significantly decreased. Dogs that had a heterozygous PDE5A status had a significantly worse 
QOL score when compared to the wildtype group after sildenafil treatment. The simple and multiple 
regression analyses revealed a significant but weak prediction for the percent reduction in QOL score 
with sildenafil treatment by plasma cGMP level and by the PDE5A:E90K polymorphic status. This study 
showed that sildenafil treatment improved PH in dogs, and the PDE5A:E90K polymorphism blunted the 
efficacy of sildenafil in terms of QOL improvement.
Pulmonary hypertension (PH) is a pathologically complex condition characterized by abnormally increased pul-
monary arterial (PA) pressure. PH is generally categorized by the underlying cause including pulmonary paren-
chymal or interstitial lung disease, pulmonary thromboembolism, cardiac disease, or idiopathic etiologies1–5. 
These underlying disorders result in elevated PA pressure by multiple mechanisms including elevations of pul-
monary venous pressure, increased pulmonary vascular resistance, and altered pulmonary blood flow2. Without 
prompt treatment of PH and its underlying condition, PH often induces further vasoconstriction, vascular 
smooth muscle proliferation, and microthrombus formation in the pulmonary vasculature leading to worsening 
of PH and ultimately right-sided heart failure6,7.
Sildenafil is an orally active selective PDE5 inhibitor that has been used for treating PH in humans and other 
species including dogs8–13. The main beneficial effect of sildenafil in patients with PH is believed to result from 
accumulation of cGMP in the pulmonary vascular smooth muscle due to inhibition of cGMP catabolism14–17. 
Sildenafil has further been demonstrated to decrease PA resistance by preventing PA wall proliferation18,19. 
Sildenafil effects are not limited to the pulmonary circulation as it also increases the cGMP concentration in the 
myocardium and thus may enhance cardiac function and prevent hypertrophy in mice with chronic pressure over-
load20. In dogs, there are several studies investigated the response to sildenafil therapy in experimentally-induced 
and naturally-occurring PH12,13,21–25. These experimental models of PH in dogs were induced either by hypoxic 
pulmonary vasoconstriction or pulmonary thromboembolism23,25–27. These experiments reported that short-term 
sildenafil therapy significantly decreased mean PA pressure. Several small prospective and retrospective studies 
with naturally-occurring PH in dogs have also documented significantly reduced PA pressure in response to short 
and long-term sildenafil therapy, but one study reported no significant PA pressure reduction with long-term 
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sildenafil therapy leading to some contradiction of findings in the clinical setting12,13,22,24. In human patients with 
pulmonary hypertension, long-term sildenafil therapy has been considered safe and effective9,10,28,29. However, 
several complications with chronic high-dose usage of sildenafil have been reported. These side effects include 
tachycardia, dyspepsia, headache, and visual disturbance30–34. These are generally believed to be due to vasodi-
latory effects resulting from PDE5 inhibition. In dogs, long-term sildenafil is considered safe, but a large pro-
spective study has not yet documented the frequency of adverse events in dogs with long-term sildenafil therapy.
In addition, significant inter-individual variability in the response to sildenafil has been reported in humans 
and dogs35–37. The intrinsic and extrinsic causes of inter-individual variability include poor owner compliance, 
drug-to-drug interactions, and upregulation or downregulation of other mechanisms, and possible pharmacoge-
netic impacts. Several genetic polymorphisms have been identified as associated with altered efficacy of sildenafil 
in humans38–41 including variants in PDE5A42. The PDE5A gene and its promoter regions have been sequenced 
and the functional regions are well described in humans43–45. The presence of polymorphisms in PDE5A in 
humans has been linked to reduced response to nitric oxide and altered levels of cGMP8,46. Alternation of the cod-
ing sequence in PDE5A was also demonstrated to affect the binding affinity of phosphodiesterase inhibitors47. In 
dogs, a PDE5A gene polymorphism substituting a glutamic acid for lysine at the 90th amino acid (PDE5A:E90K) 
has been identified, and the homozygous polymorphism status was reported to associate with lower basal cGMP 
concentrations compared to wildtype dogs48. However, no studies have been performed to investigate the impact 
of the PDE5A:E90K polymorphism on the response to sildenafil therapy in dogs with PH. Understanding the 
functional role of identified PDE5A gene polymorphisms is key to understanding their clinical relevance.
In this study, we first aimed to confirm the quantitative and qualitative effect of long-term sildenafil therapy 
on dogs with naturally-occurring moderate or severe PH. We hypothesized that long-term sildenafil therapy sig-
nificantly reduces severity of PH, improves QOL score, and increases circulating cGMP concentrations in dogs 
with naturally-occurring moderate to severe PH. Our second aim was to determine the effect of the PDE5A:E90K 
polymorphism on sildenafil efficacy in dogs with PH. We hypothesized that the presence of the PDE5A:E90K 
polymorphism reduces response to therapy with sildenafil in cases of moderate to severe naturally-occurring PH. 
To test these hypotheses, selected echocardiographic parameters, quality of life questionnaire, and plasma cGMP 
concentrations were obtained from dogs with moderate to severe PH before and after sildenafil therapy and these 
measures were compared in dogs genotyped to have varied PDE5A genetic status. These findings will help estab-
lish the value of a possible canine model of naturally-occurring PH and determine the impact of the PDE5A gene 
mutation on the efficacy of sildenafil therapy.
Results
Animal characteristics. Forty-one dogs met the inclusion criteria and were enrolled in this study to com-
pletion. Of these, 8 dogs were Chihuahua, 5 were mixed breed, 4 each were Shih Tzu and West Highland White 
Terrier, 3 each were Jack Russell Terrier and Pomeranian, 2 each were Maltese, Pekingese, Shetland Sheepdog, 
and one each were Affenpinscher, Cavalier King Charles Spaniel, Miniature Dachshund, Miniature Schnauzer, 
Papillon, Pug, Tibetan Terrier, and Toy Poodle. Seven (17.2%) dogs had PH of post-capillary etiology with or 
without other concurrent etiology of PH, whereas 34 (82.9%) dogs had PH of pre-capillary etiology. A total of 
22 males (53.7%) and 19 females (46.3%) were enrolled. The median weight was 5.8 (IQR: 3.5–8.85) kg among 
all dogs with the median dose of sildenafil prescribed as 4.55 (IQR: 3.71–5.65) mg/kg/day overall. The mean 
age of all dogs was 11.5 (SD: ±3.65) years old. Systolic blood pressure was measured prior to enrollment to rule 
out systemic hypotension and hypertension, and median blood pressure was 125 mmHg (IQR: 115–146 mmHg) 
overall (Table 1).
On echocardiographic examination prior to the sildenafil treatment, moderate to severe PH was diagnosed 
in all dogs enrolled (Fig. 1). Of these, 16 (39%) dogs were diagnosed with moderate PH and 25 (61%) dogs were 
diagnosed with severe PH. One dog showed signs consistent with right-sided congestive heart failure. A total of 
28/41 (68.3%) dogs had septal flattening during diastole, systole or both diastole and systole.
A total of 12 dogs (29%) died or were euthanized prior to the opportunity for a reevaluation examination 25 
to 35 days after initiating sildenafil therapy (Table 1). No obvious side effects of sildenafil therapy were reported 
by the owners, and death or euthanasia of these animals is considered to be due to progression of underlying 
disease conditions. Considering remaining dogs, there was a significant reduction of PG after sildenafil treat-
ment (P = 0.0074) (Fig. 2). Other echocardiographic parameters including PVAT (P = 0.43), PVET (P = 0.44), 
Overall Wildtype Heterozygous Homozygous P-value
Sample number, n (%) 41 9 13 19
Age (year) 11.5 (±3.65) 11.0 (±4.9) 11.2 (±4.6) 12.0 (±1.98) 0.72
Male, n (%) 22 (53.7) 2 (22.2) 9 (69.2) 11 (57.9) 0.083
Post-capillary etiology, n (%) 7 (17.2) 0 (0) 3 (23.1) 4 (44.4) 0.3
Weight (kg) 5.8 (3.5–8.85) 3 (2.34–6) 6.5 (3.8–9.05) 5.8 (4.3–9.6) 0.033
Sildenafil dose (mg/kg/day) 4.55 (3.71–5.65) 5.56 (3.13–6.71) 4.41 (3.4–5.82) 4.44 (4.05–5.26) 0.56
Systolic BP (mmHg) 125 (115–146) 112 (95–148.5) 143 (124.5–157.5) 124 (114–137) 0.064
Mortality, n (%) 12 2 (22.2) 3 (23.1) 7 (36.8) 0.61
Table 1. Baseline characteristics and mortality of dogs with different PDE5A polymorphic. status. The means 
(±SD) or medians (IQR) are shown in the table based on their normality distributions. BP; blood pressure.
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and PVAT:ET (P = 0.94) were not significantly changed between pre- and post-treatment with sildenafil. The 
mean QOL score calculated based on the questionnaire was significantly reduced after sildenafil treatment, with 
a noted improvement (lower score) in QOL (P < 0.0001) (Fig. 3). Plasma cGMP concentrations were significantly 
reduced after sildenafil treatment (P = 0.014) (Fig. 4).
PDE5A:E90K genotype. With regards to the PDE5A:E90K genotype, 9/41 (22.0%) dogs were wildtype, 
13/41 (31.7%) were heterozygous, and 19/41 (46.3%) were homozygous. There were no significant differences in 
sex distribution, mean age, median body weight, etiology (pre- and post-capillary PH), and pre-treatment sys-
temic blood pressure between the genotype groups (Table 1). There were significant differences in median body 
weight among genotype groups (P = 0.033) with lower body weight in the wildtype compared to the homozy-
gous group (P = 0.041). There were no significant differences in the sildenafil dose among the genotype groups 
(Table 1). Of 12 dogs that died or were euthanized, two dogs were wildtype (2/9; 22.2%), three dogs were het-
erozygous (3/13; 23.1%), and seven dogs were homozygous (7/19; 36.8%). The mortality rates were not signifi-
cantly different between these genotype groups (P = 0.61). When variant dogs were pooled, a Fisher’s exact test 
also revealed no statistically significant difference between the two groups and outcome (P = 0.7).
Echocardiographic findings. On echocardiographic examination prior to starting sildenafil treatment, 
septal flattening was noted in 7/9 (77.8%) wildtype, 6/13 (46.2%) heterozygous, and 15/19 (78.9%) homozygous 
dogs with no significant difference in frequency among genotype groups (P = 0.12). One dog in the homozy-
gous group had signs of right-sided heart failure, and one dog in the heterozygous group had signs of both left 
and right-sided heart failure. There were no significant differences in the estimated PG values among different 
genotype groups before and after treatment. Percent reductions of PG after treatment with sildenafil were com-
pared and there were no statistically significant differences among genotype groups (Fig. 5 and Table 2). PVAT, 
PVET, and PVAT:ET before and after the sildenafil treatment were compared based on the PDE5A polymorphic 
status, and there were no statistically significant differences pre- and post-treatment among genotype groups 
Figure 1. (a) A left apical four-chamber echocardiographic view of a dog with pulmonary hypertension shows 
color-flow Doppler of a severe tricuspid regurgitation jet. (b) A spectral Doppler image was used to measure the 
peak velocity of the tricuspid regurgitation. PG was calculated using the modified Bernoulli equation (PG = 4 × 
velocity2) without any addition for estimated right atrial pressure.
Figure 2. PG before and after sildenafil treatment is shown. The bars and boxes show the median and 
interquartile ranges. The whiskers represent 1.5 times the interquartile range and the black squares indicate 
outliers. There was a significant reduction of PG after sildenafil treatment (P < 0.0074).
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(Table 3). Percent changes in these PA flow parameters were also not significantly different among genotype 
groups (Table 3). When variant (heterozygous and homozygous) dogs were pooled and compared to the wildtype 
animals, no significant differences in pre-treatment, post-treatment, and percent changes of PG, PVAT, PVET, or 
PVAT:ET were noted (Tables 2 and 3).
QOL scores. Mean QOL scores prior to administering the first dose of sildenafil were not significantly dif-
ferent among dogs with varying genotype status, whereas there was a significant difference among the geno-
type groups in the 25–35 day post-treatment QOL score (P = 0.015). Post-hoc analysis revealed a significant 
difference in the QOL scores between dogs in the wildtype and heterozygous group (P = 0.012) after treatment 
(Fig. 6), although no significant difference in the percent reduction of the QOL scores was found among different 
genotype groups (Table 4). When variant dogs were pooled and compared to the wildtype dogs, no significant 
differences in pre-treatment, post-treatment, and percent changes of QOL scores were noted (Fig. 6 and Table 4).
cGMP concentrations. Mean cGMP concentrations before and after sildenafil treatment were not signifi-
cantly different among different genotype groups (Table 5). When percent change in the plasma cGMP concen-
tration was compared in dogs with different PDE5A:E90K polymorphisms, no statistical differences among the 
genotype groups were noted. When variant dogs (heterozygous and homozygous) were pooled and compared to 
the wildtype dogs, no significant differences in the pre-treatment, post-treatment, and percent changes of cGMP 
concentrations were noted (Fig. 7 and Table 5).
Predictive modelling. The predictive value of the percent reduction in the echocardiographic parame-
ters (PG, PVAV, PVET, PVAT:ET) and plasma cGMP concentration on the percent reduction in QOL score was 
assessed by performing simple and multiple regression analyses. These assessments revealed the statistically sig-
nificant prediction of the percent reduction in QOL score by the percent reduction in cGMP concentrations with 
Figure 3. QOL scores before and after sildenafil treatment are shown. The bars show the mean and standard 
deviations. There was a significant reduction in the QOL score after sildenafil treatment (P < 0.0001).
Figure 4. Plasma cGMP concentrations before and after sildenafil treatment are shown. The bars and boxes 
show the median and interquartile ranges. The whiskers represent 1.5 times the interquartile range, and the 
black squares indicate outliers. There was a significant reduction of plasma cGMP concentration after sildenafil 
treatment (P = 0.014).
5Scientific RepoRts |          (2019) 9:6899  | https://doi.org/10.1038/s41598-019-43318-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
the simple regression analysis F (1,18) = 6.35, P = 0.021, R2 = 0.2607. Multiple regression analysis of echocardi-
ographic parameters and cGMP concentrations predicted the percent reduction of QOL score, F (3,16) = 4.54, 
P = 0.0174, R2 = 0.4599. Among all these predictive variables, only the percent change of cGMP added statistically 
significant prediction to the model (P = 0.049).
Simple and multiple regression analyses were performed to predict the effect of the independent variables 
(PDE5A genotype, dose, sex, age, the presence of septal flattening, pre-treatment blood pressure) to the depend-
ent variables (PG, PVAT, PVET, PVAT:ET, QOL score, cGMP concentration). No variables were significantly able 
to predict the dependent variables by simple regression analysis when the dogs were divided up into three groups 
(wildtype, heterozygous, and homozygous) or two groups (wildtype and variant groups). However, multiple 
regression analysis showed that these independent variables significantly predicted the percent reduction of QOL 
scores, F (2, 23) = 3.67, P = 0.0413, R2 = 0.2421. Among all predictor variables, only genotypic status (wildtype or 
variant groups) added significant prediction to the model (P = 0.043).
Figure 5. PG (a) before and (b) after sildenafil treatment was shown in the different PDE5A:E90K polymorphic 
status. The percent reduction in PG after sildenafil treatment was compared in (c) three (wildtype, heterozygous, 
and homozygous) groups and (d) two (wildtype and variant) groups. The bars and boxes show the median and 
interquartile ranges. The whiskers represent 1.5 times the interquartile range, and the black squares indicate 
outliers. PDE5A polymorphic status did not affect the PG before and after sildenafil treatment, and the percent 
reduction in PG among different genotype groups.
Variants
Wildtype Heterozygous Homozygous P-value
PG
Pre-treatment 87.75 (±13.56)
84.35 (±23.27) 0.68
74.67 (±20.97) 90.97 (±22.93) 0.061
Post-treatment 55.65 (52.42–81.72)
56.72 (46.1–71.68) 0.49
56.72 (47.63–71.6) 55.91 (39.34–86.42) 0.75
Percent reduction 0.28 (−0.13–0.35)
0.23 (0.089–0.41) 0.98
0.23 (0.15–0.32) 0.24 (0.064–0.72) 0.88
Table 2. The means (±SD) or medians (IQR) of the pressure gradient before and after sildenafil treatment, and 
percent reduction with the treatment are shown in the different genotype groups. PG: pressure gradient.
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Discussion
In this study dogs with moderate to severe PH had significant reduction of PG, improvement of QOL scores, 
and reduction of plasma cGMP concentrations after sildenafil therapy. When these parameters were compared 
in dogs with different PDE5A:E90K polymorphism status, the QOL score was significantly worse after treatment 
in dogs with the heterozygous form of PDE5A:E90K and trended towards being significantly worse in variant 
genotypes when compared to wildtype dogs. The simple and multiple regression analysis revealed a significant 
but weak prediction for the percent reduction in QOL score by plasma cGMP and PDE5A:E90K genotype status 
after sildenafil treatment.
Wildtype Heterozygous Homozygous P-value
PVAT
Pre-treatment 40 (35–47.5) 39 (32.5–57) 42 (34–55) 0.98
Post-treatment 48 (29–62) 53 (48–68) 42 (37.75–57.75) 0.88
Percent reduction −0.15 (−0.28–0.38) 0.2 (−0.061–0.66) 0.032 (−0.17–0.28) 0.41
PVET
Pre-treatment 152.8(±14.35) 174.2 (±37.91) 156.4 (±27.8) 0.16
Post-treatment 158 (145–197) 161 (134–193) 177.5 (150.5–186.3) 0.82
Percent reduction 0.068 (−0.012–0.31) −0.014 (−0.15–0.088) −0.021 (−0.090–0.32) 0.42
PVAT:ET
Pre-treatment 0.28 (0.24–0.31) 0.24 (0.18–0.31) 0.27 (0.22–0.38) 0.7
Post-treatment 0.24 (0.19–0.39) 0.33 (0.27–0.37) 0.23 (0.22–0.35) 0.25
Percent reduction −2.3 (−5.55–1.04) −2.071 (−4.47–2.61) 0.82 (−0.51–1.032) 0.42
Table 3. The means (±SD) or medians (IQR) of the pulmonary flow profile obtained during echocardiographic 
examination, PVAT, PVET, and PV AT:ET before and after sildenafil treatment, and percent reduction with 
treatment are shown in the different genotype groups. PVAT; pulmonary artery flow acceleration time, PVET; 
pulmonary artery flow ejection time, PVAT:ET; the ratio of pulmonary artery flow acceleration time to ejection 
time.
Figure 6. QOL scores before (a) and after (b) sildenafil treatment are shown for different PDE5A:E90K 
polymorphic status. The percent reduction in QOL scores after sildenafil treatment was compared among three 
(wildtype, heterozygous, and homozygous) groups (c) and two (wildtype and variant) groups. The bars show 
the mean and standard deviations with the black dots as individual values when they were normally distributed. 
The bars and boxes show the median and interquartile ranges when they were not normally distributed. 
The whiskers represent 1.5 times the interquartile range, and the black squares indicate outliers. There was 
a significant difference in QOL score between dogs in the wildtype and heterozygous groups after sildenafil 
treatment (P = 0.012).
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Variants
Wildtype Heterozygous Homozygous P-value
QOL Score
Pre-treatment 45.89 (±21.75)
40.42 (±16.9) 0.43
39.54 (±18.12) 41.1 (±16.5) 0.71
Post-treatment 9 (±6.537)
18.37 (±9.57) 0.08
21 (±11.96) 16.27 (±6.28) 0.015
Percent reduction 0.73 (0.58–0.93)
20 (12–33) 0.071
0.5 (−0.019–0,74) 0.48 (0.45–0.72) 0.19
Table 4. The means (±SD) or medians (IQR) of the QOL score obtained before and after sildenafil treatment, 
and percent reduction with treatment are shown in the different genotype groups. QOL; quality of life.
Variants
Wildtype Heterozygous Homozygous P-value
cGMP
Pre-treatment 211.8 (74.88–278.3)
109.3 (61.3–203.5) 0.35
122.4 (67.51–210.7) 102 (58.02–220.6) 0.55
Post-treatment 19.75 (8.20–159.7)
54.53 (19.5–151.7) 0.34
98.64 (36.76–160.9) 54.53 (18.1–158.4) 0.55
Percent reduction 0.78 (0.17–0.91)
0.52 (−0.088–0.78) 0.31
0.25 (0.035–0.8) 0.69(−1.55–0.81) 0.58
Table 5. The means (±SD) or medians (IQR) of the plasma cGMP concentrations obtained before and after 
sildenafil treatment, and percent reduction with treatment are shown in the different genotype groups. cGMP; 
cyclic guanosine monophosphate.
Figure 7. Plasma cGMP concentrations (a) before and (b) after sildenafil treatment are shown in the different 
PDE5A:E90K polymorphic status. The percent reduction in cGMP concentration after sildenafil treatment was 
compared in (c) three (wildtype, heterozygous, and homozygous) groups and (d) two (wildtype and variant) 
groups. The bars and boxes show the median and interquartile ranges. The whiskers represent 1.5 times the 
interquartile range and the black squares indicate outliers. There was no significant difference in the plasma 
cGMP concentration before and after the treatment. There was also no significant difference in percent changes 
of cGMP concentrations among different genotype groups.
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In the pulmonary vascular endothelium, nitric oxide (NO) is synthesized from oxygen and L-arginine cata-
lyzed by nitric oxide synthase isoenzymes (arginine-NO pathway). NO is a potent vasodilator and an inhibitor of 
vascular smooth muscle cell proliferation by activating guanylyl cyclase which increases cGMP production49,50. 
Apart from the arginine-NO pathway, nitrite (NO2−) and nitrate (NO3−) also increases cGMP concentration by 
bio-transformation to NO via both non-enzymatic and enzymatic mechanisms (nitrate-nitrite-NO pathway)51–53. 
Circulating nitrite (NO3−) is endogenously produced from the arginine-NO pathway, and also determined by the 
amount of dietary intake of nitrates (NO3−). In the present study, plasma or tissue concentrations of L-arginine, 
nitrite, nitrate, and NO were not measured, and the dominant pathways of NO and subsequent cGMP produc-
tion in these patients were not determined54,55. It is possible that dogs with high nitrate intake could have higher 
nitrite levels and subsequent cGMP production. This represents an additional possible cause of interindividual 
variability for sildenafil treatment response. Despite this possible confounding variable, this remains an unlikely 
cause of the inter-individual variability observed in this study since the baseline cGMP concentrations were not 
significantly different between genotype groups.
Sildenafil has been used with overall encouraging result as a treatment for canine PH12,13,21. One prospective 
and several retrospective studies demonstrated that sildenafil significantly decreased PA pressure in the majority 
of dogs with PH13,21,22. However, another study reported no significant reduction in PA pressure after sildenafil 
treatment despite finding a significant improvement in quality of life with sildenafil therapy12. In our study, PG 
values were significantly reduced after sildenafil treatment, but other echocardiographic parameters routinely 
used to assess PH severity12 including PVAT, PVET, and PVAT:ET were not significantly altered. In addition, the 
QOL score was significantly improved after sildenafil treatment in dogs with moderate to severe PH. Although 
no significant correlation was identified in the present study between percent changes of PG and QOL scores, it 
is reasonable to speculate that the observed reduction in PG is due to sildenafil treatment and is associated with 
improved QOL score. This is consistent with some of the previous studies of PH in humans. Interestingly, the only 
prospective randomized placebo controlled study in dogs with PH failed to identify any significant reduction of 
PA pressure between the sildenafil or placebo groups21. The authors of this prospective study, however, stated that 
this was possibility due to type II error because of withdrawal of dogs during the study period. The present study 
did not include a placebo control group, and thus we are not able to confirm the improvement in PG, QOL scores 
and cGMP concentration are entirely a result of sildenafil therapy. Although unlikely given the typical clinical 
progression of canine PH, the authors cannot rule out that the improvement of these parameters was partially due 
to improvement of the underlying disease condition during the study period. Despite these confounding variables 
of clinical research, in the present study, a significantly lower cGMP concentration was measured after sildenafil 
treatment. There was no significant correlation between the percent reductions in PG and cGMP concentration, 
yet there was a weak but significant correlation between the percent reductions of plasma cGMP concentration 
and the QOL score. These results might also suggest that the lower circulating cGMP concentration could result 
from improvement in PH secondary to sildenafil therapy and/or improvement of the underlying disease condi-
tion with subsequent reductions in endogenous cGMP production. While not specifically evaluated in this study, 
it is possible that the change in circulating cGMP might be considered as a potential biomarker for studying the 
response to sildenafil therapy.
It is important to consider that cGMP concentration in the pulmonary vasculature could be elevated in dogs 
after sildenafil treatment even with lower circulating plasma cGMP concentration, perhaps reflecting sequestra-
tion of cGMP at the site of action in vascular smooth muscle and sustained activity locally. However, previous 
studies showed a high degree of correlation between plasma cGMP concentration and tissue cGMP concentration 
in the aorta, which was maintained after treatment with a PDE inhibitor56. Regardless of the explanation for the 
observed cGMP concentrations, a significant reduction of PG and improvement in QOL score was achieved with 
sildenafil treatment.
When dogs were categorized into two or three groups based on their PDE5A genotypes, no statistically sig-
nificant differences in any echocardiographic parameters (PG, PVAT PVET, PVAT:ET) before or after sildenafil 
treatment were noted. Although the previous study reported the basal plasma cGMP concentrations were sig-
nificantly lower in healthy dogs with PDE5A polymorphisms, the plasma cGMP concentrations were not sig-
nificantly different before sildenafil treatment among different genotype groups in this study48. This could be 
explained by overall activation of arginine-NO pathway by PH in dogs with any polymorphic status or type II 
error due to small sample size. More importantly, post-treatment QOL scores were significantly different among 
groups due to significantly worse QOL score in the heterozygous group than the wildtype group. The absolute 
and percent reduction in QOL scores were not significantly different among groups but there was a trend toward 
reduced improvement in the QOL score in variant dogs compared to the wildtype dogs. Our findings suggest that 
the PDE5A gene mutation does not significantly alter basal echocardiographic and biochemical parameters, but 
it alters observable QOL effects in sildenafil treated dogs with moderate to severe PH. This discrepancy among 
the PDE5A genotypes however cannot be fully explained by the effect of sildenafil on the plasma cGMP con-
centrations alone. The failure to observe a significant change in the homozygous genotype group may simply be 
due to type II error as there is a comparably small number of dogs in this group and other possible mechanisms 
impacting QOL score by genotype should be investigated in the future.
Sildenafil is also known to act as an anti-oxidant and could improve the clinical condition of dogs with PH 
by reducing the oxidative stress from PH or the underlying disease condition26,27,57–60. This could be a potential 
reason that the QOL score in dogs with PH was improved without significant improvement of PA pressure in 
previous studies12. The level of oxidative stress could be evaluated by measuring various biomarkers61–65, however 
assessments of oxidative stress were not measured as part of this clinical trial. In future studies, these oxidative 
stress markers could be assessed concurrently to determine the efficacy of sildenafil for PH, and to determine the 
impact of the PDE5A mutation on the efficacy of sildenafil in dogs with PH.
9Scientific RepoRts |          (2019) 9:6899  | https://doi.org/10.1038/s41598-019-43318-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
The findings of this study pointed out several findings of translational importance. Although there are mul-
tiple canine models of PH reported in previous studies, these only represent experimentally-induced acute PH 
models. Canine naturally-occurring PH has been previously reported but these studies are almost exclusively 
retrospective uncontrolled studies with contradictory results. Our study was a prospective controlled clinical trial 
with long-term sildenafil therapy for dogs with naturally-occurring moderate to severe PH, and we establish that 
this canine model is a reasonable choice for further experimental studies to determine long-term efficacy of med-
ical and surgical interventions for patients with PH of various etiologies in various species. In addition, it is the 
first study to report associations between a PDE5A gene mutation and efficacy of sildenafil in dogs with PH. This 
finding signifies the importance of investigating the similar genetic mutations in PDE5A genes in human patients 
with PH to better understand the inter-individual variation of the efficacy of sildenafil. It further represents an 
opportunity for personalized medicine that could enable clinicians to make personalized clinical recommenda-
tions guided by genotype.
In the present study, there are several limitations. Based on the previous study conducted by one of the authors 
using apparently healthy dogs, the polymorphic genotype was expected to be common with more than 75% of the 
canine population possessing the polymorphism48. It was thus difficult to enroll the PDE5A wildtype dogs to fully 
satisfy the statistical power. Indeed, some of the values assessed, including the absolute and percent changes of 
cGMP concentrations before and after the treatment, were trending toward a significant difference, which may be 
indicative of a type II error due to small sample size. The small sample size of dogs with PH was therefore a pos-
sible cause of a failure of rejecting the null hypothesis in the present study. Future studies aiming to address these 
questions should thus include larger numbers of dogs with PH, especially targeting PDE5A wildtype and homozy-
gous dogs to elucidate the impact of PDE5A gene mutation. Secondly, the present study enrolled dogs with PH 
caused by any underlying diseases and with concurrent diseases, which could alter plasma cGMP concentrations 
as well as impact response to sildenafil therapy. Although this is less likely to be a significant problem since none 
of the enrolled dogs had significant systemic illness other than PH and the underlying cardiopulmonary diseases, 
future studies may aim to enroll dogs with a more homogenous PH etiology, although this will limit the direct 
applicability to the clinical experience, which our study mimicked through its open enrollment. Potentially signif-
icant confounding variables include nitrite and nitrate concentrations as well as oxidative stress level due to cardi-
opulmonary and concurrent disease conditions, and future studies should consider measuring the concentrations 
of nitrate and nitrite as well as oxidative stress markers. Third, PA pressure was estimated by echocardiographic 
examination in this study. The gold standard for diagnosing PH is a direct measurement of PA pressure by right 
heart catheterization. In people, there are conflicting findings as to the correlation of PA pressure measured by 
echocardiography and by right heart catheterization. In clinical veterinary medicine, the right heart catheteriza-
tion is not routinely used to measure the PA pressure due to its high degree of invasiveness and the requirement 
for anesthesia which falsely reduces measured pressure gradients. As a future direction, the long-term effect 
of sildenafil in dogs and the pharmacogenomic effect of the PDE5A mutation on interindividual-variability of 
sildenafil therapy could be assessed in the experimental setting through right heart catheterization and echocar-
diographic evaluations. Finally, in this study, cGMP concentration was measured in the plasma obtained from 
the dogs. Although cGMP in plasma is strongly correlated with that in the endothelium of other species, it is 
unknown if this strong correlation could be maintained in dogs with sildenafil treatment.
This study demonstrated that sildenafil treatment significantly reduces PG, reduces plasma cGMP concen-
tration, and improves QOL scores in dogs with moderate to severe PH. The percent reduction in QOL score is 
correlated with the percent change in cGMP but not percent change in PG. The changes in echocardiographic 
and biochemical parameters observed with sildenafil treatment were not affected by the genotype of PDE5A gene, 
but the improvement in QOL score appears blunted in dogs with the heterozygous allele state of this mutation. 
Therefore, inter-individual variability in the efficacy of sildenafil as a treatment of PH could be partially explained 
this PDE5A mutation. Further studies are warranted to fully understand the association of this PDE5A mutation 
and the efficacy of sildenafil in treating moderate to severe canine PH and to further document the role of genetic 
testing and individualized medicine in this disease.
Methods
Animals and study settings. This study was approved by the Animal Care and Use Committee of the 
University of California-Davis and performed in accordance with relevant guidelines and regulations. Informed 
owner consent was obtained for all dogs prior to enrollment. All dogs were enrolled between January 2014 and 
August 2016. Dogs were evaluated prior to enrollment by performing a general physical examination, cardiovas-
cular examination, complete echocardiogram, and systolic blood pressure measurement using sphygmomanom-
eter and Doppler device at the William R. Pritchard Veterinary Medical Teaching Hospital of the University of 
California-Davis. Dogs were enrolled if the tricuspid regurgitation estimated systolic pulmonary pressure gradi-
ent (PG) was ≥50 mmHg in the absence of outflow tract obstruction, pulmonic stenosis, systemic hypotension 
(SBP < 90 mmHg) or systemic hypertension (SBP > 180 mmHg). Any medications except those that directly alter 
PA pressure were allowed but these medications and their doses could not be modified. Uncontrolled left-sided 
congestive heart failure was considered as an exclusion criterion as institution of new cardiac medications was 
not permitted.
The etiology of PH was categorized broadly into two basic groups: post-capillary and pre-capillary etiologies. 
The post-capillary group included dogs with left heart disease with and without other concurrent causes of PH. 
The pre-capillary group included dogs with an absence of left heart diseases (i.e., normal left atrial size) based 
on the echocardiographic examination5. After enrollment, the dog owners completed the previously validated 
17 point QOL questionnaire, which assessed the presence and severity of clinical signs impacting breathing and 
functional status on a scale of 0 (not at all) to 5 (very much)66. A 4 mL whole blood sample was then obtained 
from dogs and aliquoted to EDTA and sodium-citrated tubes for extracting genomic DNA and for measuring 
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cGMP concentrations, respectively. Sildenafil was prescribed to enrolled dogs at a dose range of 1.0–2.0 mg/kg 
orally every 8–12 hours for a period of 25–35 days. A reevaluation was performed in 25–35 days that included 
general physical examination, cardiovascular examination, and echocardiographic examination. A 2 mL of whole 
blood was obtained in a sodium-citrated tube for repeated cGMP measurement, and the dog owners completed a 
second and final QOL questionnaire during the recheck examination.
Echocardiography. Complete echocardiographic examination including 2-dimensional, M-mode, and 
Doppler evaluations was performed on all dogs by a board-certified veterinary cardiologist (JS) or by a car-
diology resident with the direct supervision of a board-certified veterinary cardiologist (JS, LV, CGH) using a 
4- to 12 MHz sector-array transducer (S12–4) with color and spectral Doppler capability (Philips IE33, Philips 
Healthcare, Andover, MA). Dogs were placed in right and left lateral recumbency for echocardiographic exami-
nation. In accordance with the guidelines of the American Society of Echocardiography, all measurements were 
performed using the standard offline analysis software (Syngo Dynamics Workplace, Siemens Medical Solutions, 
USA, Inc., Malvern, PA) by using a leading-edge to leading-edge technique of measurement on at least three 
cardiac cycles67. The following echocardiographic parameters were recorded at baseline and 25–35 day after 
sildenafil therapy: PA flow velocity (PV), PA flow acceleration time (PVAT), PA flow ejection time (PVET), the 
ratio of PVAT to PVET (PVAT:ET), presence or absence of septal flattening during systole or diastole, presence 
or absence of right-sided congestive heart failure evidenced by cavitary effusion. PA flow was measured from 
the right parasternal short axis view using pulsed-wave Doppler imaging. Tricuspid regurgitation jet identified 
by color Doppler images was aligned parallel to the plane of the ultrasound interrogation cursor (Fig. 1). Peak 
tricuspid jet velocity was measured only when the patient was in sinus rhythm. PG was calculated using the 
modified Bernoulli equation (PG = 4 × velocity2) without adding estimated right atrial pressure. Moderate pul-
monary hypertension was categorized as a PG of 50–75 mmHg while severe pulmonary hypertension was set at 
a PG > 75 mmHg.
DNA sequencing. Four milliliters of whole blood were obtained from cephalic or saphenous veins. Two 
milliliters of whole blood were collected in an EDTA tube for isolation of genomic DNA. Genomic DNA was 
extracted using a commercially available kit (Puregene, Gentra Systems, Minneapolis, MN), in accordance with 
the manufacturer’s protocol. Briefly, red blood cells in EDTA whole blood samples were lysed with red blood cell 
lysis solution, followed by ten-minute incubation at room temperature and centrifugation. The white blood cell 
pellet was then resuspended in cell lysis solution overnight at room temperature. Samples were then placed on ice 
for ten minutes after the addition of one milliliter of protein precipitation solution. DNA was precipitated using 
100% isopropanol, cleaned up with 70% ethanol, and resuspended in 100–200 ul of TE buffer. Genomic DNA 
was quantified and evaluated for quality and purity using NanoDrop One Spectrophotometer (Thermo Fisher).
Previously published primers for the PDE5A:E90K polymorphism in dogs were utilized for polymerase chain 
reaction (PCR)48. PCR reaction was performed with LA Taq with GC Buffer (Takara Bio USA) following the man-
ufacturer protocol. Briefly, the PCR reaction contained 0.25 ul of LA Taq, 12.5 ul of 2x GC Buffer 1, 4 ul of 2.5 mM 
dNTP, 1 ul of 20 ng/ul forward primer, 1 ul of 20 ng/ul reverse primer, 1 ul of 20 ng/ul sample DNA, and 4.25 ul 
of ddH2O. The amplification protocol included an initial one-minute denaturing step at 94 °C, 30 cycles at 94 °C 
for 30 seconds, 55 °C for 30 seconds, 72 °C for two minutes, and a final elongation step at 72 °C for five minutes. 
Successful PCR amplification was verified by electrophoresis on a 1% agarose gel with 5 µL of each PCR product 
and 2 µL of 6x loading dye. Residual amplification primers and dNTPs were removed from the PCR product using 
ExoSAP-IT (Affymetrix, Santa Clara, CA). Amplicons for both forward and reverse primers were sequenced at 
the UC Davis Sequencing Facility (Davis, CA) using ABI Prism 3730 Genetic Analyzer. Sequences were ana-
lyzed using Lasergene Software (DNASTAR, Inc) to determine the presence of the PDE5A:E90K polymorphism. 
Genotypes were recorded as wild type, heterozygous or homozygous.
cGMP measurement. A commercially available cGMP EIA kit (Alfa Aesar, Catalog No. BT-740, Tweksbury, 
MA) was used to measure plasma cGMP concentrations in dogs with PH. This product was validated for use in 
dogs by testing intra-assay precision (coefficient of variation < 10%), spike recovery, and dilutional linearity. 
Plasma cGMP concentration was measured for each of 41 samples in triplicate by spectrophotometry. Samples 
with >10% coefficient of variation were repeated. Plasma cGMP concentration was measured before and after 
25–35 days of sildenafil treatment.
Statistics. The sample size was calculated as to obtain an 80% power in identifying a statistically significant 
difference in response to sildenafil therapy based upon PDE5A polymorphism. The biological variable of interest 
was defined as PA pressure and the mean utilized for severely affected dogs in accordance with the literature13,21. 
The goal was to detect a difference in PG of 5–10 mmHg between PDE5A:E90K polymorphic status. Based on 
the frequencies of homozygous and heterozygous mutations in the preliminary study and an assumption of 10%, 
15%, and 20% reduction of PG in homozygous, heterozygous and wildtype groups, respectively, a minimum of 13 
dogs of each genotype category was needed to achieve 80% power with alpha of 0.05 and two-sided test48.
Normality testing was performed using D’Agostino – Pearson Omnibus testing. The echocardiographic 
parameters (PG, PVAT, PVET, PVAT:ET), QOL score, and cGMP concentrations were compared before and 
after sildenafil treatment using paired student’s t-test (parametric) or Wilcoxon matched-pairs signed rank test 
(non-parametric). Age, body weight, sildenafil dose, pre-treatment systolic blood pressure, mortality rate, echo-
cardiographic parameters, QOL score, and cGMP concentrations for each different PDE5A:E90K polymorphism 
status were compared using either an ANOVA (parametric) with subsequent Tukey’s multiple comparisons test 
or Kruskal Wallis test (non-parametric) with subsequent Dunn multiple comparisons test for continuous vari-
ables. The same variables were also compared between the two groups, wildtype and variant (heterozygous and 
1 1Scientific RepoRts |          (2019) 9:6899  | https://doi.org/10.1038/s41598-019-43318-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
homozygous) groups, using either a student’s t-test (parametric) or Mann – Whitney U-test (nonparametric). 
Categorical variables including sex distribution, outcome (death/euthanized or alive) during the study period, 
and etiology of PH (pre- or post-capillary) were compared using a Chi-square or Fisher’s exact test. Percent 
change was determined by dividing the absolute reduction value by pre-treatment value.
Correlations and predictive values of the independent variables (age, sex, weight, sildenafil dose, the presence 
of septal flattening before treatment, etiology, PDE5A genotype and pre-treatment blood pressure) to various 
dependent variables (percent changes of PG, PVAT, PVET, PVAT:ET, QOL score, and cGMP concentration) were 
assessed by performing simple and multiple regression analyses, after standard assumptions for linear regression 
were performed. Backward and forward selection techniques were performed by sequentially deleting or add-
ing the variables with P < 0.2, respectively. The predictive values of the percent changes of echocardiographic 
parameters and cGMP concentrations on the percent changes of QOL scores and cGMP concentrations were 
also assessed by performing simple and multiple regression analysis after standard assumptions of linear regres-
sion. Statistical significance was set at P = 0.05. All statistical analyses were performed on commercially available 
STATA software (Stata Corporation v14.2, College Station, TX) and GraphPad Prism software (GraphPad Prism 
v7.0c, La Jolla, CA).
Data Availability
The authors declare that all data supporting the findings of this study are available within the article or from the 
corresponding author upon request.
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